Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJR9H0)

Drug Name

CC-292 Drug Info

Synonyms

AVL-292; 1202757-89-8; spebrutinib; cc-292; UNII-DRU6NG543J; CC-292 (AVL-292); DRU6NG543J; AVL292; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; AK198940; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; Btk inhibitor CC-292; Spebrutinib [USAN:INN]; Spebrutinib (USAN/INN); SCHEMBL626216; GTPL7837; CHEMBL3301625; EX-A255; AVL 292

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 59174488
CAS Number: CAS 1202757-89-8
TTD Drug ID: DMJR9H0

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.838	3.897	5.053	5.897

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic lymphocytic leukaemia

ICD Disease Classification

2A82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.54E-01	0.24	0.56

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.